- Nan Chen on Impact of Anthracyclines in High Genomic Risk Node Negative HR
Positive HER2 Negative Breast Cancer
Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the
impact of anthracyclines in high genomic risk node-negative...
from: The ASCO Post
|
- Research Offers Further Insight into Chemo Scheduling for Early Breast
Cancer
Study sought to optimize chemo dosing schedule for patients with
node-positive or high-risk node-negative breast cancer.
from: Cleveland Clinic
|
- SABCS 2024: Anthracyclines May Improve Survival in High-Risk Breast Cancer,
But Risks Must Be Weighed
In an interview with Pharmacy Times®, Nan Chen, MD, breast medical
oncologist from the University of Chicago, shared that patient with high...
from: Pharmacy Times
|
- Homing in on Anthracyclines' High-Risk Niche in Early Breast Cancer
SAN ANTONIO -- Women with larger, genomically high-risk breast cancers had
significantly lower risk of distant metastasis with chemotherapy...
from: MedPage Today
|
- Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves
survival in high-risk breast cancer patients
Patients with early-stage, node-negative, hormone receptor (HR)-positive,
HER2- negative breast cancer who have a high risk of recurrence...
from: News-Medical
|
|
